A vaccine administered during pregnancy is significantly cutting hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials reporting a reduction of more than 80 per cent. The jab, provided to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by enhancing maternal immunity and transferring immunity through the placenta. A major new study analysing nearly 300,000 births across England between September 2024 and March 2025 has demonstrated the vaccine’s “excellent protection” during the timeframe when infants are most vulnerable to the virus. RSV affects roughly half of all newborns and remains one of the primary reasons of hospital admission in babies under one year old, with more than 20,000 serious cases recorded annually across the UK.
How the immunisation safeguards at-risk babies
RSV, or respiratory syncytial virus, is a common respiratory infection that affects roughly half of all newborns in their first few months of life. The virus can range from causing mild, cold-like symptoms to triggering severe chest infections that cause babies to struggle to breathe and feed. In the most serious cases, the inflammation in the lungs becomes life-threatening, with small numbers of infants dying from the infection each year. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the distressing nature of serious RSV infections: “In babies with bad infections you can see their chest and lungs struggling, as they try to pull enough oxygen in. This is very, very frightening as a parent, frightening for good reason.”
The pregnancy vaccine operates by stimulating the mother’s immune system to produce defence proteins, which are then passed to the foetus through the placenta. This mother-derived protection provides newborns with instant defence from the moment of birth, precisely when they are most vulnerable to RSV. The latest research demonstrates that protection reaches approximately 85% when the vaccine is administered four weeks or more before delivery. Even briefer gaps between vaccination and birth can still deliver meaningful protection, with evidence indicating that a two-week gap is adequate to shield babies delivered prematurely. Dr Watson advises pregnant women to receive the vaccine on schedule, whilst noting that protection remains possible even if given later in the third trimester.
- Nearly 85 per cent coverage when vaccinated 4 weeks before birth
- Maternal antibodies passed through placenta protect newborns from day one
- Coverage possible with two-week gap before early delivery
- Vaccination during the third trimester still provides significant infant protection
Persuasive evidence from the latest research
The performance of the pregnancy RSV vaccine has been established through a thorough investigation carried out throughout England, examining data from nearly 300,000 babies born between September 2024 and March 2025. This constitutes approximately nine out of ten of all births during that six-month period, providing comprehensive and reliable evidence of the vaccine’s actual performance. The study’s findings have been supported by the UK Health Security Agency as showing “excellent protection” for newborns during their earliest and most vulnerable period. The scope of this study gives healthcare professionals and parents-to-be with assurance in the vaccine’s established performance across varied populations and settings.
The results reveal a notable picture of the vaccine’s protective effectiveness. More than 4,500 babies were hospitalised with RSV throughout the study period, with the overwhelming majority being infants whose mothers did not receive the vaccination. This clear distinction highlights the vaccine’s essential role in preventing serious illness in newborns. The decrease in hospital admissions surpassing 80 per cent represents a significant public health achievement, helping to prevent thousands of infants from experiencing the alarming and potentially severe symptoms connected with severe RSV infection. These findings reinforce the importance of the vaccination programme launched in the UK in 2024.
Study methodology and scope
The research analysed birth and hospitalisation records from England over a six-month period, capturing data on approximately 90% of all births during this timeframe. By examining nearly 300,000 babies born to both vaccinated and unvaccinated mothers, researchers were in a position to determine clear comparisons of RSV infection levels and hospital admissions. The substantial sample size and comprehensive nature of the data collection ensured that findings were statistically significant and indicative of the general population, rather than isolated cases or small subgroups.
The study specifically recorded hospital admissions for RSV among infants born to mothers who had been given the vaccine at different timepoints before delivery. This allowed researchers to determine the minimum time required between vaccination and birth for maximum protection, as well as to determine whether protection remained meaningful with briefer timeframes. The methodology assessed actual clinical results rather than controlled laboratory conditions, providing real-world data of how the vaccine performs when administered across different clinical contexts and patient circumstances throughout the final three months of pregnancy.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Grasping RSV and the dangers
Respiratory syncytial virus, typically known as RSV, is one of the leading causes of hospitalisation in infants under one year of age across the United Kingdom. The virus affects approximately half of all newborns during their first few months of life, with severity varying dramatically from minor cold-type symptoms to severe, life-threatening chest infections. Over 20,000 infants require intensive hospital care for RSV annually in the UK alone, placing considerable pressure on paediatric wards and neonatal units during busier periods.
The infection causes deep inflammation in the lungs and airways, making it dangerously difficult for infected babies to feed and breathe effectively. Parents frequently observe their babies fighting for breath, their chests rising whilst they work to get adequate oxygen into their compromised lungs. Whilst the majority of babies recover with supportive care, a limited though important proportion perish from RSV complications yearly, making immunisation programmes a vital health service objective for safeguarding the most vulnerable and youngest individuals in the population.
- RSV causes inflammation in lungs, leading to severe breathing difficulties in infants
- Nearly 50% of infants contract the virus in their first few months of life
- Symptoms vary between mild colds to serious chest infections that threaten life requiring hospitalisation
- More than 20,000 UK infants need serious hospital treatment for RSV annually
- Few infants succumb to RSV complications annually in the UK
Uptake rates and specialist advice
Since the RSV vaccine programme began in 2024, health officials have highlighted the importance of pregnant women receiving their jab at the best time for greatest protection. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, has underscored that the timing is essential for ensuring newborns benefit from the strongest possible immunity from birth. Whilst the evidence indicates that vaccination performed at least four weeks prior to delivery provides approximately 85% protection, experts encourage women to receive their vaccine as soon as feasible from 28 weeks of pregnancy onwards to maximise the antibodies passed to their babies via the placenta.
The messaging from health authorities remains clear: pregnant women ought to prioritise getting vaccinated during their third trimester, even if circumstances mean they cannot get vaccinated at the ideal window. Dr Watson has reassured expectant mothers that protection is still achievable with shorter intervals between immunisation and delivery, including even a two-week gap for those delivering slightly early. This adaptable strategy acknowledges the practical demands of pregnancy whilst ensuring strong protection for vulnerable newborns during their most critical early months when RSV poses the greatest risk of serious illness.
Regional differences in immunisation
Whilst the RSV vaccine programme has been launched across England, uptake rates and implementation timelines have varied across various areas and NHS trusts. Some areas have achieved higher vaccination coverage among eligible pregnant women, whilst others continue working to boost understanding and availability of the jab. These geographical variations reflect variations in healthcare infrastructure, communication strategies, and local engagement efforts, though the national data shows consistently strong protection regardless of geographical location.
- NHS trusts rolling out multiple messaging strategies to engage with pregnant women
- Inconsistencies across regions in vaccine uptake rates in different parts of England necessitate strategic intervention
- Local healthcare systems tailoring initiatives to suit local requirements and situations
Real-world impact and parent viewpoints
The vaccine’s impressive effectiveness translates into tangible benefits for families throughout the United Kingdom. With more than 20,000 babies admitted to hospital annually due to RSV before the rollout of this safeguarding intervention, the 80% drop in admissions equates to thousands of infants spared from severe infection. Parents no more face the upsetting situation of seeing their babies labour to breathe or struggle to eat, symptoms that characterise severe RSV infections. The vaccine has substantially transformed the landscape of neonatal lung health, giving expectant mothers a active means to protect their most vulnerable children during those crucial first weeks.
For families like that of Malachi, whose serious RSV infection resulted in severe brain damage, the vaccine’s accessibility carries profound emotional significance. His mother’s advocacy for the jab underscores the profound consequences that treatable infection can cause to young children and their families. Whilst Malachi’s experience precedes the vaccine programme, his story resonates strongly with parents now provided with protection. The knowledge that such grave complications—hospital stay, oxygen dependency, neurological damage—are now largely avoidable has offered substantial reassurance to women in pregnancy during their third trimester, transforming what was once an predictable seasonal threat into a controllable health concern.